Fortschr Neurol Psychiatr 2001; 69(10): 460-467
DOI: 10.1055/s-2001-17564
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Cholesterin, Omega-3-Fettsäuren und Suizidrisiko

Empirische Evidenz und pathophysiologische HypothesenCholesterol, Omega-3 Fatty Acids, and Suicide Risk: Empirical Evidence and Pathophysiological HypothesesJ.  Brunner1 , K.  G.  Parhofer2 , P.  Schwandt2 , T.  Bronisch1
  • 1 Max-Planck-Institut für Psychiatrie, München (Direktor: Prof. Dr. Dr. F. Holsboer)
  • 2 Medizinische Klinik und Poliklinik II Großhadern, Ludwig-Maximilians-Universität München (Direktor: Prof. Dr. B. Göke)
Diese Arbeit wurde vom Bundesministerium für Bildung und Forschung (BMBF) im Rahmen des Förderschwerpunktes „Kompetenznetze in der Medizin” gefördert.
Further Information

Publication History

Publication Date:
02 October 2001 (online)

Zusammenfassung

Klinische Studien wiesen bei psychiatrischen Patienten mit verschiedenen Diagnosen auf einen möglichen Zusammenhang zwischen niedrigen Cholesterinkonzentrationen und Suizidalität, Depression, Impulsivität und Aggressivität hin. Diese Assoziation kann nicht allein durch den Gewichtsverlust im Rahmen depressiver Erkrankungen hinreichend erklärt werden. Eine Reihe von Befunden deutet darauf hin, dass ein serotonerges Defizit im präfrontalen Kortex dazu prädisponieren könnte, in psychosozialen Belastungssituationen impulsiv und autoaggressiv zu handeln. Ausgehend von den Befunden zu serotonergen Veränderungen bei suizidalen Patienten wurde eine neurobiologisch determinierte Vulnerabilität für suizidales Verhalten postuliert. In-vitro-Untersuchungen und Tierexperimente sowie humane In-vivo-Studien unterstützen die Annahme, dass eine Cholesterinreduktion in neuronalen Membranen die serotonerge Neurotransmission hemmen könnte. Aufgrund neuester Befunde wurde die Hypothese formuliert, dass ein Mangel an mehrfach ungesättigten Fettsäuren, insbesondere Omega-3-Fettsäuren, das Risiko für Depressionen und Suizidhandlungen erhöhen könnte. Untersuchungen an gesunden Probanden deuten darauf hin, dass eine erhöhte Zufuhr von Omega-3-Fettsäuren mit der Nahrung die serotonerge Aktivität erhöhen und dadurch impulsive und aggressive Verhaltensweisen hemmen könnte. Frühere epidemiologische Studien zeigten eine statistische Assoziation zwischen niedrigen Cholesterinspiegeln und einem erhöhten Suizidrisiko. Dies konnte jedoch in neueren epidemiologischen Untersuchungen mit größeren Fallzahlen und längeren Beobachtungszeiträumen nicht repliziert werden; vielmehr zeigte sich sogar eine positive Korrelation zwischen Cholesterinkonzentrationen und Suizidrisiko. Die kürzlich publizierten Interventionsstudien zeigten, dass Statine (Simvastatin, Lovastatin, Pravastatin) nicht zu einer Erhöhung der Suizidmortalität führen.

Abstract

Studies in psychiatric patients described an association between lower serum cholesterol concentrations, suicidality, depression, impulsivity, and aggression which is not entirely attributable to depression-related malnutrition and weight-loss. Several lines of evidence suggest that a serotonergic deficit in the prefrontal cortex may predispose vulnerable subjects to impulsive, autoaggressive, and suicidal behaviour in stressful life-events. In-vitro studies, animal experiments, and human in-vivo studies support the hypothesis that cholesterol reduction may contribute to the serotonergic abnormalities which have been postulated in suicidal subjects. Recently it was hypothesized that decreased consumption of polyunsaturated fatty acids, especially omega-3 fatty acids, may be a risk factor for depression and suicide. Data from human studies in healthy volunteers suggest that increasing the dietary intake of omega-3 fatty acids may increase central serotonergic activity and reduce impulsive and aggressive behaviours. Earlier epidemiological studies showed an association between low cholesterol concentrations and increased suicide risk. Recent epidemiological studies with greater samples and longer follow-up periods, however, even showed a positive correlation between cholesterol concentrations and suicide risk after controlling for potential confounding variables. Large trials of statins (simvastatin, lovastatin, pravastatin) did not show an increase of suicide mortality.

Literatur

  • 1 Papassotiropoulos A, Hawellek B, Frahnert C, Rao G S, Rao M L. The risk of acute suicidality in psychiatric inpatients increases with low plasma cholesterol.  Pharmacopsychiat. 1999;  32 1 - 4
  • 2 Maes M, Smith R, Christophe A, Vandoolaeghe E, Van Gastel V, Neels H, Demedts P, Wauters A, Meltzer H Y. Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers.  Acta Psychiatr Scand. 1997;  95 212 - 221
  • 3 Kunugi H, Takei N, Aoki H, Nanko S. Low serum cholesterol in suicide attempters.  Biol Psychiatry. 1997;  41 196 - 200
  • 4 Yeragani V K, Balon R, Pohl R, Ramesh C. Imipramine treatment and increased serum cholesterol levels.  Canadian Journal of Psychiatry. 1989;  34 (8) 845
  • 5 Brown D W, Ketter T A, Crumlish J, Post R M. Carbamazepine-induced increases in total serum cholesterol: clinical and theoretical implications.  J Clin Psychopharmacol. 1992;  12 431- 437
  • 6 Spivak B, Lamschtein C, Talmon Y, Guy N, Mester R, Feinberg I, Kotler M, Weizman A. The impact of clozapine treatment on serum lipids in chronic schizophrenic patients.  Clinical Neuropharmacology. 1999;  22 (2) 98 - 101
  • 7 Morgan R E, Palinkas L A, Barrett-Connor E L, Wingard D L. Plasma cholesterol and depressive symptoms in older men.  Lancet. 1993;  341 75 -79
  • 8 Horsten M, Wamala S P, Vingerhoets A, Orth-Gomer K. Depressive symptoms, social support, and lipid profile in healthy middle-aged women.  Psychosomatic Medicine. 1997;  59 521 - 528
  • 9 Bronisch T. The relationship between suicidality and depression.  Archives of Suicide Research. 1996;  2 235 - 254
  • 10 Brunner J, Bronisch T. Neurobiologische Korrelate suizidalen Verhaltens.  Fortschr Neurol Psychiat. 1999;  67 391 - 412
  • 11 Virkkunen M. Serum cholesterol levels in homicidal offenders.  Neuropsychobiology. 1983;  10 65 - 69
  • 12 Golomb B A, Stattin H, Mednick S. Low cholesterol and violent crime.  Journal of Psychiatric Research. 2000;  34 301 - 309
  • 13 Freedman D S, Byers T, Barrett D H, Stroup N E, Eaker E, Monroe-Blum H. Plasma lipid levels and psychologic characteristics in men.  Am J Epidemiol. 1995;  141 507 - 517
  • 14 New A S, Sevin E M, Mitropoulou V, Reynolds D, Novotny S L, Callahan A, Trestman R L, Siever L J. Serum cholesterol and impulsivity in personality disorders.  Psychiatry Res. 1999;  85 145 - 150
  • 15 Steinert T, Woelfle M, Gebhardt R P. No correlation of serum cholesterol levels with measures of violence in patients with schizophrenia and non-psychotic disorders.  Eur Psychiatry. 1999;  14 346 - 348
  • 16 Lester D. The concentration of neurotransmitter matabolites in the cerebrospinal fluid of suicidal individuals: a meta-analysis.  Pharmacopsychiat. 1995;  28 45 - 50
  • 17 Mann J J. The neurobiology of suicide.  Nature Medicine. 1998;  4 25 - 30
  • 18 Engelberg H. Low serum cholesterol and suicide.  Lancet. 1992;  339 727 - 729
  • 19 Hawton K, Cowen P, Owens D, Bond A, Elliott M. Low serum cholesterol and suicide.  Br J Psychiatry. 1993;  162 818 - 825
  • 20 Fawcett J, Busch K A, Jacobs D, Kravitz H M, Fogg L. Suicide: a four-pathway clinical-biochemical model.  Ann NY Acad Sci. 1997;  836 288 - 301
  • 21 Block E R, Edwards D. Effect of plasma membrane fluidity on serotonin transport by endothelial cells.  Am J Physiology. 1987;  253 C672 - C678
  • 22 Heron D S, Shinitzky M, Hershkowitz M, Samuel D. Lipid fluidity markedly modulates the binding of serotonin to mouse brain membranes.  Proc Natl Acad Sci USA. 1980;  77 (12) 7463 - 7467
  • 23 Shih J C, Ohsawa R. Differential effect of cholesterol on two types of 5-hydroxytryptamine binding sites.  Neurochemical Research. 1983;  8 (6) 701 - 710
  • 24 Papaphilis A, Deliconstantinos G. Modulation of serotonergic receptors by exogenous cholesterol in the dog synaptosomal plasma membrane.  Biochemical Pharmacology. 1980;  29 3325 - 3327
  • 25 Maguire P A, Druse M J. The influence of cholesterol on synaptic fluidity, dopamine D1 binding and dopamine-stimulated adenylate cyclase.  Brain Res Bull. 1989;  23 69 - 74
  • 26 Salter M. Low serum cholesterol and suicide.  Lancet. 1992;  339 1169
  • 27 Kaplan J R, Shively C A, Fontenot M B, Morgan T M, Howell S M, Manuck S B, Muldoon M F, Mann J J. Demonstration of an association among dietary cholesterol, central serotonergic activity, and social behavior in monkeys.  Psychosomatic Medicine. 1994;  56 479 - 484
  • 28 Muldoon M F, Kaplan J R, Manuck S B, Mann J J. Effects of a low-fat diet on brain serotonergic responsivity in cynomolgus monkeys.  Biol Psychiatry. 1992;  31 739 - 742
  • 29 Kaplan J R, Muldoon M F, Manuck S B, Mann J J. Assessing the observed relationship between low cholesterol and violence-related mortality. Implications for suicide risk.  Ann NY Acad Sci. 1997;  836 57 - 80
  • 30 Steegmans P HA, Fekkes D, Hoes A W, Bak A AA, van der Does E, Grobbee D E. Low serum cholesterol concentrations and serotonin metabolism in men.  Br Med J. 1996;  312 221
  • 31 Ringo D L, Lindley S E, Faull K F, Faustman W O. Cholesterol and serotonin: seeking a possible link between blood cholesterol and CSF 5-HIAA.  Biol Psychiatry. 1994;  35 957 - 959
  • 32 Alvarez J C, Cremniter D, Lesieur P, Gregoire A, Gilton A, Macquin-Mavier I, Jarreau C, Spreux-Varoquaux O. Low blood cholesterol and low platelet serotonin levels in violent suicide attempters.  Biol Psychiatry. 1999;  45 1066 - 1069
  • 33 Severus W E, Ahrens B. Omega-3 fatty acids in psychiatry.  Nervenarzt. 2000;  71 58 - 62
  • 34 Hibbeln J R, Umhau J C, George D T, Salem N. Do plasma polyunsaturates predict hostility and depression?. In: Simopoulos, AP, Pavlou, KN (Hrsg.). Nutrition and Fitness: Metabolic and Behavioral Aspects in Health and Disease. World Rev Nutr Diet Basel: Karger 1997: 175-186
  • 35 Hibbeln J R, Salem N. Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy.  Am J Clin Nutr. 1995;  62 1 - 9
  • 36 Adams P B, Lawson S, Sanigorski A, Sinclair A J. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression.  Lipids. 1996;  31 (suppl) 157 - 161
  • 37 Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer H. Fatty acid composition in major depression: decreased ω3 fractions in cholesteryl esters and increased C20 : 4ω3/C20 : 5ω3 ratio in cholesteryl esters and phospholipids.  Journal of Affective Disorders. 1996;  38 35 - 46
  • 38 Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer H Y. Lowered ω3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients.  Psychiatry Res. 1999;  85 275 - 291
  • 39 Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety.  Journal of Psychiatric Research. 1999;  33 181- 214
  • 40 Stoll A L, Severus E, Freeman M P, Rueter S, Zboyan H A, Diamond E, Cress K K, Marangell L B. Omega 3 fatty acids in bipolar disorder. A preliminary double-blind, placebo-controlled trial.  Arch Gen Psychiatry. 1999;  56 407- 412
  • 41 Delion S, Chalon S, Hérault J, Guilloteau D, Besnard J C, Durand G. Chronic dietary α-linolenic acid deficiency alters dopaminergic and serotoninergic neurotransmission in rats.  J Nutr. 1994;  124 2466 - 2476
  • 42 Hibbeln J R, Linnoila M, Umhau J C, Rawlings R, George D T, Salem N. Essential fatty acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics.  Biol Psychiatry. 1998;  44 235 - 242
  • 43 Virkkunen M E, Horrobin D F, Jenkins D K, Manku M S. Plasma phospholipid essential fatty acids and prostaglandins in alcoholic, habitually violent, and impulsive offenders.  Biol Psychiatry. 1987;  22 1087 - 1096
  • 44 Hamazaki T, Sawazaki M, Asaoka E, Nagao Y, Nishimura N, Yazawa K, Kuwamori T, Kobayashi M. The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study.  J Clin Invest. 1996;  97 1129 - 1133
  • 45 Hibbeln J R, Umhau J C, Linnoila M, George D T, Ragan P W, Shoaf S E, Vaughan M R, Rawlings R, Salem N. A replication study of violent and nonviolent subjects: cerebrospinal fluid metabolites of serotonin and dopamine are predicted by plasma essential fatty acids.  Biol Psychiatry. 1998;  44 243 - 249
  • 46 Vartiainen E, Puska P, Pekkanen J, Tuomilehto J, Lönnqvist J, Ehnholm C. Serum cholesterol concentrations and mortality from accidents, suicide, and other violent causes.  Br Med J. 1994;  13 445 - 447
  • 47 Zureik M, Courbon D, Ducimetière P. Serum cholesterol concentration and death from suicide in men: Paris prospective study I.  Br Med J. 1996;  313 649 - 651
  • 48 Partonen T, Haukka J, Virtamo J, Taylor P R, Lönnqvist J. Association of low serum total cholesterol with major depression and suicide.  British Journal of Psychiatry. 1999;  175 259 - 262
  • 49 Iribarren C, Reed D M, Wergowske G, Burchfiel C M, Dwyer J H. Serum cholesterol level and mortality due to suicide and trauma in the Honolulu heart program.  Arch Int Med. 1995;  155 695 - 700
  • 50 Tanskanen A, Vartiainen E, Tuomilehto J, Viinamäki H, Lehtonen J, Puska P. High serum cholesterol and risk of suicide.  Am J Psychiatry. 2000;  157 648 - 650
  • 51 Muldoon M, Manuck S B, Matthews K A. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials.  Br Med J. 1990;  301 309-314
  • 52 LaRosa J C. Cholesterol lowering and morbidity and mortality.  Current Opinion in Lipidology. 1995;  6 62 - 65
  • 53 Richter W O. Vermehrte Autoaggressivität durch cholesterinsenkende Medikamente?.  Fortschr Med. 1994;  112 507 - 508
  • 54 Muldoon M, Rossouw J E, Manuck S E, Glueck C J, Kaplan J R, Kaufmann P G. Low or lowered cholesterol and risk of death from suicide and trauma.  Metabolism. 1993;  42 (9 Suppl 1) 45 - 56
  • 55 Rubins B H, Robins S J, Collins D, Fye C L, Anderson J W, Elam M B, Faas F H, Linares E, Schaefer E J, Schectman G, Wilt T J, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.  N Engl J Med. 1999;  341 410 - 418
  • 56 Duits N, Bos F M. Depressive symptoms and cholesterol-lowering drugs.  Lancet. 1993;  341 114
  • 57 Lechleitner M, Hoopichler F, Konwalinka G, Patsch J R, Braunsteiner H. Depressive symptoms in hypercholesterolaemic patients treated with pravastatin.  Lancet. 1992;  340 910
  • 58 Delva N J. Matthews DR. Cowen PJ. Brain serotonin (5-HT) neuroendocrine function in patients taking cholesterol-lowering drugs.  Biol Psychiatry. 1996;  39 100 - 106
  • 59 Scandinavian Simvastatin Survival Study G roup. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S).  Lancet. 1994;  344 1383 - 1389
  • 60 Shepherd J, Cobbe S M, Ford I, Isles C G, Lorimer A R, MacFarlane P W, McKillop J H, Packard C J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.  N Engl J Med. 1995;  333 (20) 1301 - 1307
  • 61 Downs J R, Clearfield M, Weis S, Whitney E, Shapiro D R, Beere P A, Langendorfer A, Stein E A, Kruyer W, Gotto A M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels.  JAMA. 1998;  279 1615 -1622
  • 62 Sacks F M, Pfeffer M A, Moye L A, Rouleau J L, Rutherford J D, Cole T G, Brown L, Warnica J W, Arnold J MO, Wun C C, Davis B R, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.  N Engl J Med. 1996;  335 101 - 109
  • 63 The long-term intervention with pravastatin in ischaemic disease (LIPID) study g roup. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.  N Engl J Med. 1998;  339 1349 - 1357
  • 64 LaRosa J C, He J, Vupputuri S. Effects of statins on risk of coronary heart disease. A meta-analysis of randomized controlled trials.  JAMA. 1999;  282 2340 - 2346
  • 65 Strandberg T E, Räikkönen K, Partinen M, Pihl S, Vanhanen H, Miettinen T A. Associations of cholesterol lowering by statins with anger and hostility in hypercholesterolemic men.  Biol Psychiatry. 1994;  35 575 - 577
  • 66 Fritze J, Schneider B, Lanczik M. Autoaggressive behaviour and cholesterol.  Neuropsychobiology. 1992;  26 180 - 181
  • 67 Modai I, Valevski A, Dror S, Weizman A. Serum cholesterol levels and suicidal tendencies in psychiatric inpatients.  J Clin Psychiatry. 1994;  55 252 - 254
  • 68 Sullivan P F, Joyce P R, Bulik C M, Mulder R T, Oakley-Browne M. Total cholesterol and suicidality in depression.  Biol Psychiatry. 1994;  36 472 - 477
  • 69 Gallerani M, Manfredini R, Caracciolo S, Scapoli C, Molinari S, Fersini C. Serum cholesterol concentrations in parasuicide.  Br Med J. 1995;  310 1632 - 1636
  • 70 Golier J A, Marzuk P M, Leon A C, Weiner C, Tardiff K. Low serum cholesterol level and attempted suicide.  Am J Psychiatry. 1995;  152 419 - 423
  • 71 Wolfersdorf M, Michelsen A, Keller F, Maier V, Fröscher W, Kaschka W P. Serum cholesterol, triglyceride and suicide in depressed patients.  Archives of Suicide Research. 1996;  2 161 - 170
  • 72 Apter A, Laufer N, Bar-Sever M, Har-Even D, Ofek H, Weizman A. Serum cholesterol, suicidal tendencies, impulsivity, aggression, and depression in adolescent psychiatric inpatients.  Biol Psychiatry. 1999;  46 532 - 541
  • 73 Glueck C J, Tieger M, Kunkel R, Hamer T, Tracy T, Speirs J. Hypocholesterolemia and affective disorders.  Am J Med Sci. 1994;  308 (4) 218 - 225
  • 74 Maes M, Delanghe J, Meltzer H Y, Scharpé S, D’Hondt P, Cosyns P. Lower degree of esterification of serum cholesterol in depression: relevance for depression and suicide research.  Acta Psychiatr Scand. 1994;  90 252 - 258
  • 75 Lindberg G, Larsson G, Setterlind S, Råstam L. Serum lipids and mood in working men and women in Sweden.  J Epidemiol Community Health. 1994;  48 360 - 363

Dr. med. Jürgen Brunner

Max-Planck-Institut für Psychiatrie

Kraepelinstraße 10

80804 München

Email: E-mail: jbrunner@mpipsykl.mpg.de

    >